PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-12.38%
Negative net income growth while TRVN stands at 54.20%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-27.15%
Both reduce yoy D&A, with TRVN at -8.89%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-5631.45%
Negative yoy deferred tax while TRVN stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
0.93%
SBC growth while TRVN is negative at -1.96%. John Neff would see competitor possibly controlling share issuance more tightly.
-32.67%
Both reduce yoy usage, with TRVN at -162.44%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
107.56%
AP growth well above TRVN's 199.07%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-665.24%
Negative yoy usage while TRVN is 421.32%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
5631.45%
Some yoy increase while TRVN is negative at -265.41%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-36.10%
Both yoy CFO lines are negative, with TRVN at -0.55%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
78.08%
Lower CapEx growth vs. TRVN's 199.90%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.08%
Investing outflow well above TRVN's 50.08%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
66.67%
We repay more while TRVN is negative at -1390100.00%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
210.14%
Stock issuance far above TRVN's 385.55%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.